Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Inv. presentation
Appointed director
Verrica Pharmaceuticals Inc. (VRCA) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/08/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/08/2023 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Verrica Pharmaceuticals Reports Second Quarter 2023 Financial Results"
07/27/2023 8-K Investor presentation
Docs: "Company Presentation",
"Company Presentation"
07/27/2023 144 Form 144 - Report of proposed sale of securities:
07/27/2023 144 Form 144 - Report of proposed sale of securities:
07/27/2023 144 Form 144 - Report of proposed sale of securities:
07/27/2023 144 Form 144 - Report of proposed sale of securities:
07/26/2023 8-K Quarterly results
07/25/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
07/25/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
07/25/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
07/25/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
07/24/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
07/24/2023 8-K Quarterly results
06/12/2023 4 Ballaron Craig (Director) has filed a Form 4 on Verrica Pharmaceuticals Inc.
Txns: Granted 10,384 options to buy @ $5.7, valued at $59.2k
06/12/2023 4 Eichenfield Lawrence (Director) has filed a Form 4 on Verrica Pharmaceuticals Inc.
Txns: Granted 10,384 options to buy @ $5.7, valued at $59.2k
06/12/2023 4 Nguyen Diem (Director) has filed a Form 4 on Verrica Pharmaceuticals Inc.
Txns: Granted 10,384 options to buy @ $5.7, valued at $59.2k
06/12/2023 4 PRYGOCKI MARK A SR (Director) has filed a Form 4 on Verrica Pharmaceuticals Inc.
Txns: Granted 10,384 options to buy @ $5.7, valued at $59.2k
06/08/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
05/09/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/09/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
05/09/2023 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Verrica Pharmaceuticals Reports First Quarter 2023 Financial Results"
04/21/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/21/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
04/21/2023 ARS Form ARS - Annual Report to Security Holders:
03/06/2023 10-K Annual Report for the period ended December 31, 2022
03/06/2023 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2022 Financial Results"
02/22/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
02/14/2023 SC 13G/A PERCEPTIVE ADVISORS LLC reports a 12.3% stake in Verrica Pharmaceuticals Inc.
02/02/2023 8-K Quarterly results
01/24/2023 8-K Other Events  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
12/20/2022 EFFECT Form EFFECT - Notice of Effectiveness:
12/19/2022 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
11/07/2022 S-3 Form S-3 - Registration statement under Securities Act of 1933:
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy